Survival and death causes in differentiated thyroid carcinoma

被引:243
作者
Eustatia-Rutten, CFA [1 ]
Corssmit, EPM [1 ]
Biermasz, NR [1 ]
Pereira, AM [1 ]
Romijn, JA [1 ]
Smit, JW [1 ]
机构
[1] Leiden Univ, Med Ctr, Dept Endocrinol & Metab Dis, NL-2300 RC Leiden, Netherlands
关键词
D O I
10.1210/jc.2005-1322
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Survival studies in differentiated thyroid carcinoma (DTC) may be biased because they have been performed in heterogeneous populations. In addition, specific death causes in DTC have not been documented well in the literature. Aims: The aim of our study was to investigate survival and specific death causes in a homogeneous cohort of DTC patients. Patients: Patients included 366 consecutive patients with DTC who had all been treated according to the same protocol for initial therapy and follow-up. Methods: Prognostic factors for DTC-related death were analyzed by univariate Cox regression analysis, followed by stepwise multivariate Cox regression analysis. Standardized mortality rates (SMR) were calculated using normal mortality rates for the entire Dutch population. Results: During follow-up of 8.3 +/- 4.6 yr, 82 patients (22.4%) died. At multivariate Cox-regression analysis, tumor stage T4, distant metastases, and advanced age were associated with an increased relative risk for DTC-related death. SMR for the entire group was 2.32. This could be explained by increased SMR in patients with stage T4, distant metastases, or advanced age. Death causes could be verified in 80 patients: 52 died of DTC, 28 due to other causes. Ten of the 20 patients with stage T1-3M0 died from thyroid carcinoma. Conclusion: Relative risk for thyroid cancer-related death and SMR are significantly increased in patients with stage T4 and M1 or advanced age. Although death risk is not increased in T1-3M0 patients, DTC contributed significantly to mortality in all patient categories.
引用
收藏
页码:313 / 319
页数:7
相关论文
共 37 条
[1]  
AKSLEN LA, 1991, CANCER RES, V51, P1234
[2]  
[Anonymous], TNM CLASSIFICATION M
[3]  
Bellantone R, 1998, J SURG ONCOL, V68, P237, DOI 10.1002/(SICI)1096-9098(199808)68:4<237::AID-JSO6>3.0.CO
[4]  
2-5
[5]   A population-based analysis of survival factors in differentiated and medullary thyroid carcinoma [J].
Bhattacharyya, N .
OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 2003, 128 (01) :115-123
[6]   FOLLICULAR THYROID-CANCER TREATED AT THE MAYO-CLINIC, 1946 THROUGH 1970 - INITIAL MANIFESTATIONS, PATHOLOGICAL FINDINGS, THERAPY, AND OUTCOME [J].
BRENNAN, MD ;
BERGSTRALH, EJ ;
VANHEERDEN, JA ;
MCCONAHEY, WM .
MAYO CLINIC PROCEEDINGS, 1991, 66 (01) :11-22
[7]   Differentiated thyroid carcinoma: Comparison between papillary and follicular carcinoma in a single institute [J].
Chow, SM ;
Law, SCK ;
Au, SK ;
Leung, TW ;
Chan, PTM ;
Mendenhall, WM ;
Lau, WH .
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2002, 24 (07) :670-677
[8]   Prognostic factors in well-differentiated thyroid carcinoma [J].
Cushing, SL ;
Palme, CE ;
Audet, N ;
Eski, S ;
Walfish, PG ;
Freeman, JL .
LARYNGOSCOPE, 2004, 114 (12) :2110-2115
[9]   MORBIDITY AND MORTALITY IN FOLLICULAR THYROID-CANCER [J].
DEGROOT, LJ ;
KAPLAN, EL ;
SHUKLA, NS ;
SALTI, G ;
STRAUS, FH .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1995, 80 (10) :2946-2953
[10]   NATURAL-HISTORY, TREATMENT, AND COURSE OF PAPILLARY THYROID-CARCINOMA [J].
DEGROOT, LJ ;
KAPLAN, EL ;
MCCORMICK, M ;
STRAUS, FH .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1990, 71 (02) :414-424